Focaltherics™ 宣布,其针对子宫内膜异位症的商业化 Focal One® 项目已在欧洲成功启动,并完成了对首批患者的治疗。这标志着该创新疗法在欧洲市场的首次商业化应用取得重要进展。
Focaltherics™ 宣布,其针对子宫内膜异位症的商业化 Focal One® 项目已在欧洲成功启动,并完成了对首批患者的治疗。这标志着该创新疗法在欧洲市场的首次商业化应用取得重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.